Venous thromboembolism and cancer: Risks and outcomes

Circulation

Volumn 107, Issue SUPPL. 23, 2003, Pages

  Lee, Agnes Y Y ^a,b   Levine, Mark N ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON GENERAL HOSPITAL   (Canada)

Author keywords

Coagulation; Neoplasm; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

AGE; BLEEDING; BRAIN CANCER; BREAST CANCER; CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COLON CANCER; DISEASE ASSOCIATION; DISEASE SEVERITY; GENETIC SCREENING; HUMAN; IDIOPATHIC DISEASE; IMMOBILIZATION; LIFE EXPECTANCY; LUNG CANCER; OCCULT CANCER; OVARY CANCER; PANCREAS CANCER; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; SURGERY; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM; INCIDENCE; LUNG EMBOLISM; NEOPLASM; PROGNOSIS; VEIN THROMBOSIS;

ANTICOAGULANTS; INCIDENCE; NEOPLASMS; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; PULMONARY EMBOLISM; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0038718518     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000078466.72504.AC     Document Type: Review

References (59)

1. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg. 1988;208:227-240.
2. Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J. 1980;73:841-843.
3. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488.
4. Prins MH, Hettiarachchi RJ, Lensing AW, et al. Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see? Thromb Haemost. 1997;78:121-125.
5. Hettiarachchi RJ, Lok J, Prins MH, et al. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer. 1998;83:180-185.
6. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585-593.
7. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-815.
8. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479-484.
9. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89:1673-1682.
10. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:404-407.
11. Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996;14:2731-2737.
12. Clahsen PC, van de Velde CJ, Julien JP, et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol. 1994;12:1266-1271.
13. Rivkin SE, Green S, Metch B, et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1994;12:2078-2085.
14. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991;9:286-294.
15. Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990;8:1005-1018.
16. Weiss RB, Tormey DC, Holland JF, et al. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep. 1981;65:677-679.
17. Wall JG, Weiss RB, Norton L, et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B Study. Am J Med. 1989;87:501-504.
18. von Tempelhoff GF, Dietrich M, Hommel G, et al. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol. 1996;14:2560-2568.
19. Goodnough LT, Saito H, Manni A, et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer. 1984;54:1264-1268.
20. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343:886-889.
21. von Tempelhoff GF, Dietrich M, Niemann F, et al. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost. 1997;77:456-461.
22. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. 2000;89:640-646.
23. Quevedo JF, Buckner JC, Schmidt JL, et al. Thromboembolism in patients with high-grade glioma. Mayo Clin Proc. 1994;69:329-332.
24. Priest JR, Ramsay NK, Steinherz PG, et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 1982;100:984-989.
25. Gugliotta L, Mazzucconi MG, Leone G, et al. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Eur J Haematol. 1992;49:63-66.
26. Ottinger H, Belka C, Kozole G, et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non-Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 1995;54:186-194.
27. Seifter FJ, Young RC, Longo DL. Deep venous thrombosis during therapy for Hodgkin's disease. Cancer Treat Rep. 1985;69:1011-1013.
28. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-1615.
29. Desai AA, Vogelzang NJ, Rini BI, et al. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002;95:1629-1636:
30. Marx GM, Steer CB, Harper P, et al. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! J Clin Oncol. 2002;20:1446-1448.
31. Kuenen BC, Rosen L, Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 2002;20:1657-1667.
32. Bona RD. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Hemost. 1999;25:147-155.
33. Couban S, Goodyear M, Burnell M, et al. A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer. Blood. 2002;100:703a.
34. Walshe U, Malak SF, Eagan J, et al. Complication rates among cancer patients with peripherally inserted central catheters. J Clin Oncol. 2002;20:3276-3281.
35. 506 mutation in unselected oncology patients. Am J Med. 1996;101:406-412.
36. Fareed J, Hoppensteadt D, Bacher P, et al. Hypercoagulable state in cancer patients is independent of molecular defects of thrombophilia. Presented at the Am Society of Hematology Meeting, Philadelphia, PA, December 6-10, 2002. Blood. 2002;100:270a.
37. Sack GH, Jr., Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977;56:1-37.
38. Lieberman JS, Borrero J, Urdanetam E, et al. Thrombophlebitis and cancer. JAMA. 1961;177:542-545.
39. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78:285-291.
40. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
41. Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost. 1999;25:137-145.
42. Prandoni P, Lensing AW, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128-1133.
43. Aderka D, Brown A, Zelikovski A, et al. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer. 1986;57:1846-1849.
44. Monreal M, Fernandez-Llamazares J, Perandreu J, et al. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost. 1997;78:1316-1318.
45. Rajan R, Levine M, Gent M, et al. The occurrence of subsequent malignancy in patients presenting with deep vein thrombosis: results from a historical cohort study. Thromb Haemost. 1998;79:19-22.
46. Ahmed Z, Mohyuddin Z. Deep vein thrombosis as a predictor of cancer. Angiology. 1996;47:261-265.
47. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anti-coagulation Trial. N Engl J Med. 2000;342:1953-1958.
48. Baron JA, Gridley G, Weiderpass E, et al. Venous thromboembolism and cancer. Lancet. 1998;351:1077-1080.
49. Sørensen UT, Mellemkj'r L, Steffensen FH, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338:1169-1173.
50. Piccioli A, Prandoni P. Idiopathic venous thromboembolism as a manifestation of cancer. Haemostasis. 2001;31(suppl 1):37-39.
51. Cornuz J, Pearson SD, Creager MA, et al. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med. 1996;125:785-793.
52. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in cancer. N Engl J Med. In press.
53. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer. 1984;53:2046-2052.
54. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, et al. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost. 1999;82:947-952.
55. Zacharski LR, Meechan KR, Algarra SM, et al. Clinical trials with anticoagulant and antiplatelet therapies. Cancer Metastasis Rev. 1992;11:421-431.
56. Kakkar AK, Kadziola Z, Williamson RC, et al. on behalf of the Fragmin Advanced Malignancy Outcome Study. Low molecular weight heparin therapy and survival in advanced cancer. Blood. 2002;100:148a.
57. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
58. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992;326:1240-1245.
59. Soørensen HT, Mellemkj'r L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846-1850.